All Oncology News

Funds will help support rare cancer research and families in need.

Topline results from the MONALESSA-7 trial showed that ribociclib met its primary endpoint for progression-free survival in premenopausal women with hormone-receptor

Mathieu Lupien, MD, discusses this analysis of the influence of mutations on the epigenetics of prostate cancer.

Charles Drake, MD, PhD, discusses the current status of both PARP inhibitors and immunotherapy in prostate cancer, emphasizing that immunotherapy is still very much a player in the prostate cancer field, with ongoing trials exploring checkpoint inhibitors.

E. David Crawford, MD, discusses the controversy surrounding the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, as well as the role of prostate-specific antigen testing for men with prostate cancer.

The FDA today lifted clinical holds placed on 2 phase I trials investigating a gene-edited allogeneic CAR T-cell therapy known as UCART123.

Andrea Apolo, MD, discusses the combination of cabozantinib plus nivolumab and ipilimumab, as well as the latest data on avelumab in urothelial carcinoma.

Nivolumab reduced the risk of death by 26% compared with everolimus in patients with previously treated advanced renal cell carcinoma.

Adam Waxman, MD, discusses emerging regimens for patients with multiple myeloma.

The European Medicines Agency (EMA) has received a Marketing Authorization Application (MAA) for tisagenlecleucel (Kymriah) for 2 forms of advanced lymphoma.

The FDA has approved alectinib (Alecensa) for the frontline treatment of patients with ALK-positive metastatic non-small cell lung cancer.

Paul Sabbatini, MD, discusses the recent data surrounding IP and dose-dense therapy and the next steps for both treatment approaches in ovarian cancer.

Mario M. Leitao, Jr, MD, FACOG, FACS, discusses how surgery retains its imperative role in ovarian cancer and sheds light on the challenges that still remain.

Clinical trials help community practices attract patients, inspire oncologists, and lower costs, but forming a program can be daunting to the uninitiated.

The FDA has approved vemurafenib as a treatment for patients with Erdheim-Chester disease.

The first annual Luminary Awards in GI Cancers honoring five outstanding individuals who have devoted their time, talent and resources to improving the care for patients and families affected by GI cancers, will be presented Friday, Dec. 1 at the 8th Annual Ruesch Center Symposium: Fighting a Smarter War on Cancer in Washington.

In phase Ib results from the KEYNOTE-028 trial, pembrolizumab (Keytruda) was found to be active in cervical cancer while demonstrating safety results similar to previous studies with the PD-1 inhibitor.

Alfred L. Garfall, MD, MS, discussed the treatment and management of patients with multiple myeloma, with a focus on maintenance therapy, CAR T-cell therapy, and the role of transplant.

According to phase III results from the FOLL05 trial, the combination of rituximab plus cyclophosphamide, vincristine, and prednisone produced survival results comparable with standard-of-care regimens in patients with advanced symptomatic follicular lymphoma.

Edward A. Stadtmauer, MD, sheds light on the future of chimeric antigen receptor T-cell therapy, systemic therapeutic advances in the field of acute myeloid leukemia, and remaining challenges in the multiple myeloma paradigm.

A supplemental new drug application has been submitted for brentuximab vedotin in combination with Adriamycin, vinblastine, dacarbazine as a frontline treatment for advanced classical Hodgkin lymphoma.

Pexidartinib met its primary endpoint of tumor response as measured by tumor size reduction in patients with symptomatic tenosynovial giant cell tumor where surgical resection is contraindicated.

The FDA has granted GSK2857916 a breakthrough therapy designation for patients with relapsed/refractory multiple myeloma.

Mary Jo Fidler, MD, discusses targeting the EGFR-gene activating mutations, first- and second-generation inhibitors, and the potential of osimertinib.

Patients with peripheral T-cell lymphoma are more likely to have superior overall survival if they have previously demonstrated event-free survival at 24 months.

More than half of elderly, treatment-naïve patients with AML assigned to treatment with guadecitabine had a composite complete response irrespective of dosage or schedule.

A newly announced CMS policy to redistribute savings under the 340B Drug Discount Program so that Medicare beneficiaries save money on copayments has garnered a mixture of praise and criticism from supporters and critics of the program.

The UK’s National Institute for Health and Care Excellence is recommending the use of atezolizumab for treatment-naïve patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-based therapy.

Michael A. Postow, MD, discusses the impressive efficacy seen with combining BRAF and MEK inhibitors for patients with melanoma.

Laura J. van’t Veer, PhD, discusses determining more accurate methods of treatment for patients with early- and late-state breast cancer based on advances in genetic testing, specifically the 70-gene prognostic signature.